Roche CEO Says US Deal May Mean Higher Swiss Drug Prices (1)

Roche Holding AG Chief Executive Thomas Schinecker said the new US drug deal signed last week could raise prices for some medicines in Switzerland.

The agreement, with nine pharmaceutical companies, is intended to lower lower drug costs for some Americans, while the firms will get a reprieve from threatened tariffs.

In comments published in Swiss newspapers Tribune de Geneve and Tages-Anzeiger, Schinecker said that prices for new products will be affected, because the US wants other nations to contribute more to medical innovation.

New drugs “will be subject to a reference system whereby each country will pay a price ...